Jun 2026 (Q2 FY26) — Aug 6, 2026
Qiagen Q2 FY26 — Exceeds Outlook with Growth Pillar Strength
Read the full callQiagen (QGEN) earnings
- Jun 2026 (Q2 FY26)
- Dec 2025
Qiagen earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Guidance
What management said, and what became of it
29 of 30 judged targets kept · 25 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Q2 FY26 adjusted diluted EPS (CER) | at least $0.60 at CER | Mar 2026 | Adjusted diluted EPS was $0.62 on both a reported basis and at CER again, above our outlook of at least $0.60 at CER. | Achieved |
| QIAstat complicated UTI panel Europe launch | by end of 2026 (Europe); rest of world 2027 | Sep 2025 | The development progresses very well, and we are still confident that this test will be available for Europe, Europe first in the second half of 2027. | Delayed |
| Q1 FY26 net sales growth (CER) | at least 1% CER (vs. $483 million in Q1 FY25) | Dec 2025 | Net sales were $492 million, up 2% on a reported basis, but down 1% at CER, and below our outlook for at least 1% growth CER. | Missed |
1 of QIAGEN N.V.'s 55 targets was missed. See which ones, and which are quietly gone. The 3 above are the free sample; 52 more targets are in the full ledger.
Claimed
- Net sales of $535 million exceeded outlook for an approximately 2% decline CER.
- Adjusted diluted EPS of $0.62 exceeded outlook of at least $0.60 CER.
- Growth pillars (Sample Technologies, QIAcuity, QDI) delivered 5% growth at CER.
- QuantiFERON returned to growth at 1% CER, offsetting reduced immigration testing demand.
- Operating cash flow for H1 FY26 was $301 million, unchanged YoY, supporting financial flexibility.
Qualified
- Diagnostic solutions declined 2% at CER, with QIAstat-Dx down 7% CER due to lower respiratory panel sales.
- PCR and nucleic acid amplification sales declined 8% at CER, impacted by weaker OEM demand.
- China sales were down low teens at CER, contributing to a 2% CER decline in Asia Pacific.
- Adjusted operating income declined 2% to $157 million, with margin slightly down to 29.4% from 29.9% YoY.
Price
$46.55 +0.91% · +$0.42
Performance −3.6% 1Y
1Y: $48.27 on 17 Oct 2025 → $46.55. High $55.66 (21 Jan 2026), low $32.63 (11 May 2026).
- Previous close
- $46.13
- 52-week range
- $32.63 – $55.66
- One year
- −4.36%
Overview
- Symbol
- QGEN
- Sector
- Health Care
- Industry
- Biological Products, (No Diagnostic Substances)
- Exchange
- US
- Currency
- USD
Guidance
What management said, and what became of it
29 of 30 judged targets kept · 25 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Q2 FY26 adjusted diluted EPS (CER) | at least $0.60 at CER | Mar 2026 | Adjusted diluted EPS was $0.62 on both a reported basis and at CER again, above our outlook of at least $0.60 at CER. | Achieved |
| QIAstat complicated UTI panel Europe launch | by end of 2026 (Europe); rest of world 2027 | Sep 2025 | The development progresses very well, and we are still confident that this test will be available for Europe, Europe first in the second half of 2027. | Delayed |
| Q1 FY26 net sales growth (CER) | at least 1% CER (vs. $483 million in Q1 FY25) | Dec 2025 | Net sales were $492 million, up 2% on a reported basis, but down 1% at CER, and below our outlook for at least 1% growth CER. | Missed |
Claimed
- Net sales of $535 million exceeded outlook for an approximately 2% decline CER.
- Adjusted diluted EPS of $0.62 exceeded outlook of at least $0.60 CER.
- Growth pillars (Sample Technologies, QIAcuity, QDI) delivered 5% growth at CER.
- QuantiFERON returned to growth at 1% CER, offsetting reduced immigration testing demand.
- Operating cash flow for H1 FY26 was $301 million, unchanged YoY, supporting financial flexibility.
Qualified
- Diagnostic solutions declined 2% at CER, with QIAstat-Dx down 7% CER due to lower respiratory panel sales.
- PCR and nucleic acid amplification sales declined 8% at CER, impacted by weaker OEM demand.
- China sales were down low teens at CER, contributing to a 2% CER decline in Asia Pacific.
- Adjusted operating income declined 2% to $157 million, with margin slightly down to 29.4% from 29.9% YoY.
The full ledger
Open QIAGEN N.V.’s full ledger
A free account opens 5 company ledgers a month. All 55 tracked commitments, with each call’s wording and source.
Call summaries
Mar 2026 (Q1 FY26) — Apr 28, 2026
Qiagen N.V. Q1 FY26 — Mixed Sales Offset by Strong Profitability and Updated Outlook
Read the full callEvery analysed call
Qiagen earnings calls (QGEN)
Financials
What the filings say
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Reserves | 1,380 | 1,178 | 1,323 | 1,792 | 2,160 | 2,457 | 2,448 | 2,748 |
| Total liabilities | 3,113 | 2,699 | 3,072 | 3,050 | 2,821 | 2,307 | 2,122 | 2,503 |
| Fixed assets | 512 | 455 | 559 | 638 | 662 | 765 | 754 | 924 |
| Investments | 235 | 130 | 117 | 185 | 688 | 390 | 489 | 260 |
| Total assets | 5,748 | 5,236 | 5,870 | 6,147 | 6,288 | 6,115 | 5,690 | 6,281 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 359 | 331 | 458 | 639 | 715 | 459 | 674 | 654 |
| Cash from investing | -211 | -222 | -443 | -202 | -727 | -88 | -249 | -305 |
| Cash from financing | 360 | -639 | -50 | -150 | -126 | -434 | -423 | -179 |
| Net cash flow | 501 | -530 | -31 | 283 | -150 | -63 | -5 | 175 |
| Capital expenditure | -110 | -118 | -133 | -190 | -129 | -150 | -167 | -201 |
| Free cash flow | 250 | 213 | 325 | 449 | 586 | 310 | 506 | 453 |
Insider filings
No filings in the last 12 months.
No officer, director or 10% owner of QGEN filed a Form 4 in this window. That is a statement about filings, not about ownership — see the note below.
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for QIAGEN N.V.
Free account. Everything above stays public.
Write why you follow QIAGEN N.V. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading